Intravascular Complications of Central Venous Catheterization in Chronic Hematological Diseases: Low Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Large Study
Clinical Lymphoma Myeloma and Leukemia · 2026
DOI: 10.1016/j.clml.2025.09.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Claudia Giordano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples,Italy. Electronic address: claudia.giorda…. Hauptthemen laut MEDLINE: Catheterization, Central Venous, Hematologic Diseases, Catheterization, Peripheral, Venous Thrombosis. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
INTRODUCTION: To evaluate the impact of long-term peripherally inserted central catheters (PICC) on symptomatic venous thrombosis (s-VT), we reviewed clinical charts of patients suffering from chronic hematological diseases with in-situ PICC placement for at least 90 days after catheterization at the Hematology Unit of the Federico II University Medical School of Naples (Italy). The period of observation was between January 2014 and December 2023. METHODS: A total of 1150 PICCs were inserted into 1150 patients at the hematologic diagnosis. Underlying chronic diseases were the following: non-Hodgkin lymphoma (n = 760, 66.1%), Hodgkin lymphoma (n = 200, 17.4%), multiple myeloma (n = 100, 8.7%), chronic lymphocytic leukemia (n = 50, 4.3%), severe aplastic anemia (n = 15, 1.3%), sickle cell disease (n = 10, 0.9%), thalassemia (n = 10, 0.9%), and hemophilia (n = 5, 0.4%). PICCs were successfully inserted in all cases. The median duration of in-situ PICC placement was 300 days (range, 120-400 days). RESULTS: A s-VT occurred in 30 cases (2.6%), with a rate of 0.13 (95% CI, 0.04-0.30) per 1000 implantation days. The median period time between PICC insertion and thrombotic episode was 30 days (range, 4-95 days). No serious complication was associated with these events. Hodgkin lymphoma (compared to the other diseases) resulted in a numerically higher incidence of PICC-related s-VT. CONCLUSION: PICCs represent a useful and safe frontline central vascular approach for patients with chronic hematologic diseases, with a thrombotic risk profile comparable to that reported with centrally inserted totally implantable venous access devices (TIVADs).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples,Italy. Electronic address: claudia.giordano@unina.it.
- Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples,Italy.
Zitieren
APA
Giordano, C., Picardi, M., Vincenzi, A., Scarpa, A., & Pane, F. (2026). Intravascular Complications of Central Venous Catheterization in Chronic Hematological Diseases: Low Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Large Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.09.011
Vancouver
Giordano C, Picardi M, Vincenzi A, Scarpa A, Pane F. Intravascular Complications of Central Venous Catheterization in Chronic Hematological Diseases: Low Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Large Study. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.09.011
BibTeX
@article{Giordano2026,
author = {Giordano, Claudia and Picardi, Marco and Vincenzi, Annamaria and Scarpa, Alessia and Pane, Fabrizio},
title = {Intravascular Complications of Central Venous Catheterization in Chronic Hematological Diseases: Low Risk with Peripherally Inserted Catheters in a Single-Center Retrospective Large Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2026},
doi = {10.1016/j.clml.2025.09.011}
}
EUVIMED